| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Doxorubicin | gCSI | pan-cancer | AAC | 0.01 | 0.9 |
| mRNA | Genentech Cpd 10 | GDSC1000 | pan-cancer | AAC | 0.0057 | 0.9 |
| mRNA | Cyclopamine | GDSC1000 | pan-cancer | AAC | -0.0096 | 0.9 |
| mRNA | SNX-2112:bortezomib (250:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.0061 | 0.9 |
| mRNA | BMS-345541 | GDSC1000 | pan-cancer | AAC | -0.0057 | 0.9 |
| mRNA | GSK690693 | GDSC1000 | pan-cancer | AAC | 0.0058 | 0.9 |
| mRNA | Nilotinib | CTRPv2 | pan-cancer | AAC | -0.0068 | 0.9 |
| mRNA | BRD-K11533227 | CTRPv2 | pan-cancer | AAC | -0.0067 | 0.9 |
| mRNA | linifanib | GDSC1000 | pan-cancer | AAC | -0.0061 | 0.9 |
| mRNA | 5-FU | CTRPv2 | pan-cancer | AAC | -0.006 | 0.9 |